Antiviral therapies for managing viral hepatitis in lymphoma patients

References

• Hope VD, Eramova I, Capurro D, et al. Prevalence and estimation of hepatitis b and c infections in the who european region: A review of data focusing on the countries outside the european union and the european free trade association. Epidemiol Infect. 2014;142(2):270–286.
   PubMed Web of Science ®Google Scholar
• Mele A, Pulsoni A, Bianco E, et al. Hepatitis c virus and b-cell non-hodgkin lymphomas: an italian multicenter case-control study. Blood. 2003;102(3):996–999.
   PubMed Web of Science ®Google Scholar
• Raimondo G, Pollicino T, Cacciola I, et al. Occult hepatitis b virus infection. J Hepatol. 2007;46(1):160–170.
   PubMed Web of Science ®Google Scholar
• Ferrari C, Penna A, Bertoletti A, et al. Cellular immune response to hepatitis b virus-encoded antigens in acute and chronic hepatitis b virus infection. J Immunology. 1990;145(10):3442–3449.
   PubMed Web of Science ®Google Scholar
• Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute hbv infection. Science. 1999;284(5415):825–829.
   PubMed Web of Science ®Google Scholar
• Guidotti LG, Isogawa M, Chisari FV. Host-virus interactions in hepatitis b virus infection. Curr Opin Immunol. 2015;36(36):61–66.
   PubMed Web of Science ®Google Scholar
• Perrillo RP. Acute flares in chronic hepatitis b: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120(4):1009–1022.
   PubMed Web of Science ®Google Scholar
• Yang H, Cao Z, Wang Z, et al. [hepatitis b virus reactivation induced by brentuximab vedotin in the treatment of hodgkin lymphoma: A case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2014;35(10):949–950.
   PubMedGoogle Scholar
• Ifuku H, Kusumoto S, Tanaka Y, et al. Fatal reactivation of hepatitis b virus infection in a patient with adult t-cell leukemia-lymphoma receiving the anti-cc chemokine receptor 4 antibody mogamulizumab. Hepatol Res. 2015;45(13):1363–1367.
   PubMed Web of Science ®Google Scholar
• de Jesus Ngoma P, Kabamba B, Dahlqvist G, et al. Occult hbv reactivation induced by ibrutinib treatment: A case report. Acta Gastroenterol Belg. 2015;78(4):424–426.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade b-cell lymphoma with the combination of chimeric anti-cd20 monoclonal antibody and chop chemotherapy. J Clin Oncol: off J Am Soc Clin Oncol. 1999;17(1):268–276.
   PubMed Web of Science ®Google Scholar
• Ng HJ, Lim LC. Fulminant hepatitis b virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol. 2001;80(9):549–552.
   PubMed Web of Science ®Google Scholar
• Hernandez JA, Diloy R, Salat D, et al. Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis b virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica. 2003;88(6): 94.
   Google Scholar
• Tsutsumi Y, Kawamura T, Saitoh S, et al. Hepatitis b virus reactivation in a case of non-hodgkin’s lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis b virus reactivation in rituximab therapy. Leuk Lymphoma. 2004;45(3):627–629.
   PubMed Web of Science ®Google Scholar
• Leung C, Tsoi E, Burns G, et al. An argument for the universal prophylaxis of hepatitis b infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening. Oncologist. 2011;16(5):579–584.
   PubMed Web of Science ®Google Scholar
• Rago A, Lichtner M, Mecarocci S, et al. Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for hbv reactivation following a rituximab-based regimen. Antivir Ther. 2010;15(6):929–932.
   PubMed Web of Science ®Google Scholar
• Oh MJ, Lee HJ. A study of hepatitis b virus reactivation associated with rituximab therapy in real-world clinical practice: A single-center experience. Clin Mol Hepatol. 2013;19(1):51–59.
   PubMedGoogle Scholar
• Yang SH, Kuo SH. Reactivation of hepatitis b virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol. 2008;87(4):325–327.
   PubMed Web of Science ®Google Scholar
• Xu X, Shang Q, Chen X, et al. Reversal of b-cell hyperactivation and functional impairment is associated with hbsag seroconversion in chronic hepatitis b patients. Cell Mol Immunol. 2015;12(3):309–316.
   PubMed Web of Science ®Google Scholar
• Hanbali A, Khaled Y. Incidence of hepatitis b reactivation following rituximab therapy. Am J Hematol. 2009;84(3):195.
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Shigematsu A, Hashino S, et al. Analysis of reactivation of hepatitis b virus in the treatment of b cell non-hodgkin’s lymphoma in hokkaido. Ann Hematol. 2009;88(4):375–377.
   PubMed Web of Science ®Google Scholar
• Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis b virus following rituximab-based regimens: a serious complication in both hbsag-positive and hbsag-negative patients. Ann Hematol. 2010;89(3):255–262.
   PubMed Web of Science ®Google Scholar
• Koo YX, Tan DS, Tan IB, et al. Hepatitis b virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis b virus infection who are receiving chemoimmunotherapy. Cancer. 2010;116(1):115–121.
   PubMed Web of Science ®Google Scholar
• Mendez-Navarro J, Corey KE, Zheng H, et al. Hepatitis b screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int. 2011;31(3):330–339.
   PubMed Web of Science ®Google Scholar
• Chen XQ, Peng JW, Lin GN, et al. The effect of prophylactic lamivudine on hepatitis b virus reactivation in hbsag-positive patients with diffuse large b-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol. 2012;29(2):1237–1241.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Hsu C, Song YQ, et al. Hepatitis b virus reactivation in b-cell lymphoma patients treated with rituximab: analysis from the asia lymphoma study group. Eur J Cancer. 2013;49(16):3486–3496.
   PubMed Web of Science ®Google Scholar
• Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis b infection in hbsag-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131(1):59–68.
   PubMed Web of Science ®Google Scholar
• Targhetta C, Cabras MG, Mamusa AM, et al. Hepatitis b virus-related liver disease in isolated anti-hepatitis b-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica. 2008;93(6):951–952.
   PubMed Web of Science ®Google Scholar
• Fukushima N, Mizuta T, Tanaka M, et al. Retrospective and prospective studies of hepatitis b virus reactivation in malignant lymphoma with occult hbv carrier. Ann Oncol. 2009;20(12):2013–2017.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan TC, Leung NW, et al. Hepatitis b virus reactivation in lymphoma patients with prior resolved hepatitis b undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4):605–611.
   PubMed Web of Science ®Google Scholar
• Ji D, Cao J, Hong X, et al. Low incidence of hepatitis b virus reactivation during chemotherapy among diffuse large b-cell lymphoma patients who are hbsag-negative/hbcab-positive: a multicenter retrospective study. Eur J Haematol. 2010;85(3):243–250.
   PubMed Web of Science ®Google Scholar
• Matsue K, Kimura S, Takanashi Y, et al. Reactivation of hepatitis b virus after rituximab-containing treatment in patients with cd20-positive b-cell lymphoma. Cancer. 2010;116(20):4769–4776.
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Zoppoli G, Sertoli MR, et al. Relevance of hbv/hbcab screening in lymphoma patients treated in the rituximab era. Int J Hematol. 2010;91(2):342–344. author reply 345-346
   PubMed Web of Science ®Google Scholar
• Koo YX, Tay M, Teh YE, et al. Risk of hepatitis b virus (hbv) reactivation in hepatitis b surface antigen negative/hepatitis b core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011;90(10):1219–1223.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Shibuya A, Tsunoda Y, et al. Re-appearance of hepatitis b virus following therapy with rituximab for lymphoma is not rare in japanese patients with past hepatitis b virus infection. Liver Int. 2011;31(3):340–347.
   PubMed Web of Science ®Google Scholar
• Sugauchi F, Tanaka Y, Kusumoto S, et al. Virological and clinical characteristics on reactivation of occult hepatitis b in patients with hematological malignancy. J Med Virol. 2011;83(3):412–418.
   PubMed Web of Science ®Google Scholar
• Matsui T, Kang JH, Nojima M, et al. Reactivation of hepatitis b virus in patients with undetectable hbsag undergoing chemotherapy for malignant lymphoma or multiple myeloma. J Med Virol. 2013;85(11):1900–1906.
   PubMed Web of Science ®Google Scholar
• Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis b virus reactivation in patients with lymphoma and resolved hepatitis b. J Clin Oncol: off J Am Soc Clin Oncol. 2013;31(22):2765–2772.
   PubMed Web of Science ®Google Scholar
• Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis b reactivation in lymphoma patients with resolved hbv infection: A prospective study. Hepatology. 2014;59(6):2092–2100.
   PubMed Web of Science ®Google Scholar
• Seto WK, Chan TS, Hwang YY, et al. Hepatitis b reactivation in patients with previous hepatitis b virus exposure undergoing rituximab-containing chemotherapy for lymphoma: A prospective study. J Clin Oncol. 2014;32(33):3736–3743.
   PubMed Web of Science ®Google Scholar
• Mozessohn L, Chan KK, Feld JJ, et al. Hepatitis b reactivation in hbsag-negative/hbcab-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat. 2015;22(10):842–849.
   PubMed Web of Science ®Google Scholar
• Mitroulis I, Hatzara C, Kandili A, et al. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis b virus infection. Ann Rheum Dis. 2013;72(2):308–310.
   PubMed Web of Science ®Google Scholar
• Varisco V, Vigano M, Batticciotto A, et al. Low risk of hepatitis b virus reactivation in hbsag-negative/anti-hbc-positive carriers receiving rituximab for rheumatoid arthritis: A retrospective multicenter italian study. J Rheumatol. 2016;43(5):869–874.
   PubMed Web of Science ®Google Scholar
• Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis b patients undergoing chemotherapy. Gastroenterology. 2003;125(6):1742–1749.
   PubMed Web of Science ®Google Scholar
• Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis b reactivation in non-hodgkin’s lymphoma: a randomized trial. Hepatology. 2008;47(3):844–853.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis b: update 2009. Hepatology. 2009;50(3):661–662.
   PubMed Web of Science ®Google Scholar
• Law JK, Ali JA, Harrigan PR, et al. Fatal postlymphoma chemotherapy hepatitis b reactivation secondary to the emergence of a ymdd mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol. 2006;81(12):969–972.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis b: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–475.
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis b virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49(5):1503–1514.
   PubMed Web of Science ®Google Scholar
• Li HR, Huang JJ, Guo HQ, et al. Comparison of entecavir and lamivudine in preventing hepatitis b reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 2011;18(12):877–883.
   PubMed Web of Science ®Google Scholar
• Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis b virus reactivation among patients with untreated diffuse large b-cell lymphoma receiving r-chop chemotherapy: a randomized clinical trial. Jama. 2014;312(23):2521–2530.
   PubMed Web of Science ®Google Scholar
• Yu S, Luo H, Pan M, et al. Comparison of entecavir and lamivudine in preventing hbv reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. Int J Clin Pharm. 2016;38:1035–1043.
   PubMed Web of Science ®Google Scholar
• Zhang MY, Zhu GQ, Shi KQ, et al. Systematic review with network meta-analysis: comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis b virus reactivation. Oncotarget. 2016;7(21):30642–30658.
   Web of Science ®Google Scholar
• Arcaini L, Merli M, Rattotti S, et al. Regression of indolent b-cell lymphoma after lamivudine prophylaxis of hepatitis b virus infection. J Clin Oncol. 2011;29(18):e543–545.
   PubMed Web of Science ®Google Scholar
• Mansoor MS, Wolfsohn DM. Resolution of small bowel follicular lymphoma with treatment of concomitant hepatitis b. J Clin Gastroenterol. 2015;49(10):885–887.
   PubMed Web of Science ®Google Scholar
• Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis b virus (hbv) DNA and risk of hbv reactivation in b-cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61(5):719–729.
   PubMed Web of Science ®Google Scholar
• Tamori A, Hino M, Kawamura E, et al. Prospective long-term study of hepatitis b virus reactivation in patients with hematologic malignancy. J Gastroenterol Hepatol. 2014;29(9):1715–1721.
   PubMed Web of Science ®Google Scholar
• Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis b virus screening for patients with cancer before therapy: american society of clinical oncology provisional clinical opinion update. J Clin Oncol. 2015;33(19):2212–2220.
   PubMed Web of Science ®Google Scholar
• Viganò M, Grossi G, Borsotti E, et al. P0655: lamivudine prophylaxis prevents hepatitis b reactivation in hbsag-negative/anti-hbc-positive patients undergoing rituximab-based chemotherapy for non-hodgkin’s b cell lymphoma. J Hepatol. 2015;62:4.
   Google Scholar
• Clarke B. Molecular virology of hepatitis c virus. J Gen Virol. 1997;78(Pt 10):2397–2410.
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis c and non-hodgkin lymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium. Clin Gastroenterol Hepatol. 2008;6(4):451–458.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Thieblemont C, Gallamini A, et al. Esmo consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral t-cell lymphoma. Ann Oncol. 2013;24(4):857–877.
   PubMed Web of Science ®Google Scholar
• Peveling-Oberhag J, Arcaini L, Hansmann ML, et al. Hepatitis c-associated b-cell non-hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol. 2013;59(1):169–177.
   PubMed Web of Science ®Google Scholar
• Bauduer F. Malt non-hodgkin’s lymphoma associated with hepatitis c virus infection treated by interferon alpha. Am J Hematol. 1996;53(3):209.
   PubMed Web of Science ®Google Scholar
• Caramaschi P, Biasi D, Carletto A, et al. [malt lymphomas of the salivary glands. Review of the literature apropos of a case in a patient with hepatitis c virus infection]. Recenti Prog Med. 1999;90(11):585–591.
   PubMedGoogle Scholar
• Moccia F, Tognoni E, Boccaccio P. The relationship between splenic marginal zone b-cell lymphoma and chronic liver disease associated with hepatitis c virus infection. Ann Ital Med Int. 1999;14(4):288–293.
   PubMedGoogle Scholar
• Patriarca F, Silvestri F, Fanin R, et al. Long-lasting complete remission of hepatitis c virus (hcv) infection and hcv-associated immunocytoma with alpha-interferon treatment. Br J Haematol. 2001;112(2):370–372.
   PubMed Web of Science ®Google Scholar
• Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis c virus infection. N Engl J Med. 2002;347(2):89–94.
   PubMed Web of Science ®Google Scholar
• Casato M, Mecucci C, Agnello V, et al. Regression of lymphoproliferative disorder after treatment for hepatitis c virus infection in a patient with partial trisomy 3, bcl-2 overexpression, and type ii cryoglobulinemia. Blood. 2002;99(6):2259–2261.
   PubMed Web of Science ®Google Scholar
• Pitini V, Arrigo C, Righi M, et al. Systematic screening for hcv infection should be performed in patients with splenic marginal zone lymphoma. Br J Haematol. 2004;124(2):252–253.
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Torello M. Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis c virus-positive patients after anti-hepatitis c virus therapy. J Clin Gastroenterol. 2004;38(4):360–363.
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis c virus-associated marginal zone lymphomas. Leukemia. 2004;18(10):1711–1716.
   PubMed Web of Science ®Google Scholar
• Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis c virus (hcv) treatment in hcv-related, low-grade, b-cell, non-hodgkin’s lymphoma: a multicenter italian experience. J Clin Oncol. 2005;23(3):468–473.
   PubMed Web of Science ®Google Scholar
• Svoboda J, Andreadis C, Downs LH, et al. Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis c virus infection. Leuk Lymphoma. 2005;46(9):1365–1368.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Suarez F, Lefrere F, et al. Splenic lymphoma with villous lymphocytes, associated with type ii cryoglobulinemia and hcv infection: a new entity? Blood. 2005;105(1):74–76.
   PubMed Web of Science ®Google Scholar
• Paulli M, Arcaini L, Lucioni M, et al. Subcutaneous ‘lipoma-like’ b-cell lymphoma associated with hcv infection: a new presentation of primary extranodal marginal zone b-cell lymphoma of malt. Ann Oncol. 2010;21(6):1189–1195.
   PubMed Web of Science ®Google Scholar
• Mazzaro C, De Re V, Spina M, et al. Pegylated-interferon plus ribavirin for hcv-positive indolent non-hodgkin lymphomas. Br J Haematol. 2009;145(2):255–257.
   PubMed Web of Science ®Google Scholar
• Oda Y, Kou T, Watanabe M, et al. Regression of b-cell lymphoma of the liver with hepatitis c virus infection after treatment with pegylated interferon-alpha and ribavirin. Dig Dis Sci. 2010;55(6):1791–1793.
   PubMed Web of Science ®Google Scholar
• Pellicelli AM, Marignani M, Zoli V, et al. Hepatitis c virus-related b cell subtypes in non hodgkin’s lymphoma. World J Hepatol. 2011;3(11):278–284.
   PubMedGoogle Scholar
• Mauro E, Pedata M, Ermacora A, et al. An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis c virus-related mixed cryoglobulinaemia and indolent non-hodgkin’s lymphoma previously treated with interferon. Blood Transfus. 2012;10(1):101–103.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent b-cell lymphomas associated with hcv infection: A study of the fondazione italiana linfomi. Ann Oncol. 2014;25(7):1404–1410.
   PubMed Web of Science ®Google Scholar
• Michot JM, Canioni D, Driss H, et al. Antiviral therapy is associated with a better survival in patients with hepatitis c virus and b-cell non-hodgkin lymphomas, anrs hc-13 lympho-c study. Am J Hematol. 2015;90(3):197–203.
   PubMed Web of Science ®Google Scholar
• Rossotti R, Travi G, Pazzi A, et al. Rapid clearance of hcv-related splenic marginal zone lymphoma under an interferon-free, ns3/ns4a inhibitor-based treatment. a case report. J Hepatol. 2015;62(1):234–237.
   PubMed Web of Science ®Google Scholar
• Sultanik P, Klotz C, Brault P, et al. Regression of an hcv-associated disseminated marginal zone lymphoma under ifn-free antiviral treatment. Blood. 2015;125(15):2446–2447.
   PubMed Web of Science ®Google Scholar
• Carrier P, Jaccard A, Jacques J, et al. Hcv-associated b-cell non-hodgkin lymphomas and new direct antiviral agents. Liver Int. 2015;35(10):2222–2227.
   PubMed Web of Science ®Google Scholar
• Lim LY, La D, Cserti-Gazdewich CM, et al. Lymphoma remission by interferon-free hcv eradication without chemotherapy. ACG Case Reports Journal. 2015;3(1):69–70.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Besson C, Frigeni M, et al. Interferon-free antiviral treatment in b-cell lymphoproliferative disorders associated with hepatitis c virus infection. Blood. 2016;128(21):2527–2532.
   Web of Science ®Google Scholar
• Peveling-Oberhag J, Arcaini L, Bankov K, et al. The anti-lymphoma activity of antiviral therapy in hcv-associated b-cell non-hodgkin lymphomas: a meta-analysis. J Viral Hepat. 2016;23:536–544.
   PubMed Web of Science ®Google Scholar
• Asselah T, Boyer V, Saadoun D, et al. Direct-acting antivirals for the treatment of hepatitis c virus infection: optimizing current ifn-free treatment and future perspectives. Liver Int. 2016;36(Suppl 1):47–57.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in hcv genotypes 2 and 3. N Engl J Med. 2014;370(21):1993–2001.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated hcv genotype 1 infection. N Engl J Med. 2014;370(16):1483–1493.
   PubMed Web of Science ®Google Scholar
• Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis c virus genotype 1-infected patients without cirrhosis: optimist-1, a phase 3, randomized study. Hepatology. 2016;64(2):370–380.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic hcv infection. N Engl J Med. 2014;370(3):211–221.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of hcv with abt-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594–1603.
   PubMed Web of Science ®Google Scholar
• Foster GR, Mangia A, Sulkowski M. Sofosbuvir and velpatasvir for patients with hcv infection. N Engl J Med. 2016;374(17):1687–1688.
   PubMed Web of Science ®Google Scholar
• Besson C, Canioni D, Lepage E, et al. Characteristics and outcome of diffuse large b-cell lymphoma in hepatitis c virus-positive patients in lnh 93 and lnh 98 groupe d’etude des lymphomes de l’adulte programs. J Clin Oncol. 2006;24(6):953–960.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Rossi D, Lucioni M, et al. The notch pathway is recurrently mutated in diffuse large b-cell lymphoma associated with hepatitis c virus infection. Haematologica. 2015;100(2):246–252.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis c virus-infected patients with diffuse large b-cell lymphoma treated with rituximab-containing chemotherapy regimens: A japanese multicenter analysis. Blood. 2010;116(24):5119–5125.
   PubMed Web of Science ®Google Scholar
• Merli M, Visco C, Spina M, et al. Outcome prediction of diffuse large b-cell lymphomas associated with hepatitis c virus infection: A study on behalf of the fondazione italiana linfomi. Haematologica. 2014;99(3):489–496.
   PubMed Web of Science ®Google Scholar
• La Mura V, De Renzo A, Perna F, et al. Antiviral therapy after complete response to chemotherapy could be efficacious in hcv-positive non-hodgkin’s lymphoma. J Hepatol. 2008;49(4):557–563.
   PubMed Web of Science ®Google Scholar
• Musto P, Dell’Olio M, La Sala A, et al. Diffuse b-large cell lymphomas (dblcl) with hepatitis-c virus (hcv) infection: clinical outcome and preliminary results of a pilot study combining r-chop with antiviral therapy. ASH Annu Meet Abstr. 2005;106(11):2447.
   Google Scholar
• Kyvernitakis A, Mahale P, Popat UR, et al. Hepatitis c virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. Biol Blood Marrow Transplant. 2016;22(4):717–722.
   PubMed Web of Science ®Google Scholar